
    
      A randomized, blinded study with a control group is proposed in this project to establish
      solidly the efficacy of xyloglucan in the treatment of acute gastroenteritis in children.

      The main variable of evaluation will be the duration of diarrhea, defined as the time it
      takes to normalize the consistency of stools (according to the Bristol or Amsterdam scale) or
      their number.

      Clinical trial in phase IV with medical product type IIa and CE marking, used in the same
      conditions in which it is marketed.
    
  